89bio Inc

$4.35 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About 89bio Inc

89Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The Company's lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). NASH is a severe form of nonalcoholic fatty liver disease (NAFLD), characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, hepatocellular carcinoma (HCC) and death. The Company is evaluating the potential opportunity for pegozafermin in these fibrosis stage F4 patients. SHTG is a condition identified by severely elevated levels of triglycerides. The Company has initiated its Phase II trial (ENTRIGUE) in SHTG patients.

Stock Analysis

last close $4.35
1-mo return 31.8%
3-mo return 62.9%
avg daily vol. 438.87T
52-week high 21.47
52-week low 2
market cap. $170M
forward pe -
annual div. -
roe -68.9%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 61.5%
baraka

Subscribe now for daily local and international financial news

Subscribe